Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low‑dose prednisone

  • Authors:
    • Haiying Song
    • Haofei Hu
    • Fei Tang
    • Changchun Cao
    • Qijun Wan
    • Yongcheng He
  • View Affiliations

  • Published online on: March 5, 2020     https://doi.org/10.3892/etm.2020.8573
  • Pages: 3369-3376
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Indicators for predicting the efficacy of mycophenolate mofetil (MMF) have so far remained elusive. The present study aimed to identify predictive indicators of the efficacy of MMF combined with low‑dose prednisone in patients with IgA nephropathy. A total of 598 patients presenting with primary IgA nephropathy at our center were screened. Patients were followed up for 18 months, where the end‑point was defined as complete clinical remission. Cox proportional hazards models were performed for analyzing the initial serum creatinine (SCr) concentration to predict incomplete clinical remission. In total, 7 of 71 patients (9.86%) were in complete clinical remission at the final visit. Logistic regression indicated that the hazard ratio (HR) for quartile 4 was significantly higher than the HR for quartile 1 (quartile 4 vs. quartile 1: HR, 2.51; 95% CI, 1.20‑5.21; P=0.01). Additional adjustment for the confounding variables, including age, sex, systolic BP, diastolic BP, proteinuria, uric acid, serum triglyceride, hemoglobin, serum albumin, serum total cholesterol and The Oxford classification of the models, did not reduce the HRs for the association between the initial SCr concentration and risk of incomplete clinical remission (quartile 4 vs. quartile 1: HR, 7.27; 95% CI, 1.21‑43.63; P=0.03). Each unit increase in the initial SCr concentration was associated with a 67 and 194% increase in the risk of incomplete clinical remission based on model 1 (95% CI, 1.02‑2.73; P=0.04) and model 2 (95% CI, 1.01‑8.60; P=0.048), respectively. In conclusion, in the present cohort of patients with IgA nephropathy treated with MMF plus low‑dose prednisone, the initial SCr concentration was an independent risk factor for incomplete clinical remission.

Related Articles

Journal Cover

May 2020
Volume 19 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Song, H., Hu, H., Tang, F., Cao, C., Wan, Q., & He, Y. (2020). Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low‑dose prednisone. Experimental and Therapeutic Medicine, 19, 3369-3376. https://doi.org/10.3892/etm.2020.8573
MLA
Song, H., Hu, H., Tang, F., Cao, C., Wan, Q., He, Y."Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low‑dose prednisone". Experimental and Therapeutic Medicine 19.5 (2020): 3369-3376.
Chicago
Song, H., Hu, H., Tang, F., Cao, C., Wan, Q., He, Y."Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low‑dose prednisone". Experimental and Therapeutic Medicine 19, no. 5 (2020): 3369-3376. https://doi.org/10.3892/etm.2020.8573